skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Join us in this regular podcast covering major industry events over the past week, as brought to you by Scrip's global team, this time for the business week ended 20 November 2020. 

In this episode, we look at results and plans for coronavirus vaccines, a US product setback, PCSK9 developments, and the latest progress in NASH.



These and other Informa Pharma Intelligence podcasts are available via SoundCloud, Apple Podcasts, Google Play and TuneIn, and also via smart speakers - just make sure you have set up at least one of these platforms as your default player for podcasts and then ask for "Pharma Intelligence podcasts".

Articles mentioned in this episode:

(Also see "Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy" - Scrip, 16 Nov, 2020.)

(Also see "Pfizer Pilots COVID-19 Immunization Plan In Four States As ‘Dry Run’" - Scrip, 17 Nov, 2020.)

(Also see "Sanofi Stunned As FDA Says No To CAD Drug Sutimlimab" - Scrip, 16 Nov, 2020.)

(Also see "Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug" - Scrip, 13 Nov, 2020.)

(Also see "Year Of NASH Upheaval Means Incremental Data At AASLD" - Scrip, 18 Nov, 2020.)

Details of the FDA/CMS summit on 7-9 December as mentioned in the podcast can be found here.

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: